Literature DB >> 9420685

The maze of myocardial perfusion imaging protocols in 1994.

F J Wackers1.   

Abstract

A confusing multitude of different myocardial perfusion imaging protocols have been proposed during the last few years. The impetus for this development was new insights in imaging with thallium 201 and the challenge to perform efficient imaging with the newly developed technetium 99m-labeled imaging agents. The practicing nuclear cardiologist is confronted with a true maze of options. This review describes in detail the various protocols, discusses advantages and disadvantages of each, and states, when appropriate, the personal preference of the author.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9420685     DOI: 10.1007/bf02984090

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  25 in total

1.  Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability.

Authors:  H Kiat; D S Berman; J Maddahi; L De Yang; K Van Train; A Rozanski; J Friedman
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

2.  Incomplete redistribution in delayed thallium-201 single photon emission computed tomographic (SPECT) images: an overestimation of myocardial scarring.

Authors:  K G Cloninger; E G DePuey; E V Garcia; G S Roubin; W L Robbins; A Nody; E E DePasquale; H J Berger
Journal:  J Am Coll Cardiol       Date:  1988-10       Impact factor: 24.094

3.  Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol.

Authors:  D Jain; F J Wackers; J Mattera; M McMahon; A J Sinusas; B L Zaret
Journal:  J Nucl Med       Date:  1993-08       Impact factor: 10.057

4.  Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201.

Authors:  G M Pohost; L M Zir; R H Moore; K A McKusick; T E Guiney; G A Beller
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

5.  Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study.

Authors:  D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

6.  Impact of regional ventricular function, geometry, and dobutamine stress on quantitative 99mTc-sestamibi defect size.

Authors:  A J Sinusas; Q Shi; P J Vitols; R C Fetterman; P Maniawski; B L Zaret; F J Wackers
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

7.  Rapid back to back adenosine stress/rest technetium-99m teboroxime myocardial perfusion SPECT using a triple-detector camera.

Authors:  T Chua; H Kiat; G Germano; K Takemoto; G Fernandez; Y Biasio; J Friedman; D Berman
Journal:  J Nucl Med       Date:  1993-09       Impact factor: 10.057

8.  Comparison of same-day protocols using technetium-99m-sestamibi myocardial imaging.

Authors:  J Heo; J Kegel; A S Iskandrian; V Cave; B B Iskandrian
Journal:  J Nucl Med       Date:  1992-02       Impact factor: 10.057

9.  Immediate thallium-201 reinjection following stress imaging: a time-saving approach for detection of myocardial viability.

Authors:  B L van Eck-Smit; E E van der Wall; A F Kuijper; A H Zwinderman; E K Pauwels
Journal:  J Nucl Med       Date:  1993-05       Impact factor: 10.057

10.  Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging.

Authors:  V Dilsizian; T P Rocco; N M Freedman; M B Leon; R O Bonow
Journal:  N Engl J Med       Date:  1990-07-19       Impact factor: 91.245

View more
  9 in total

1.  Reinjection of thallium for detection of viable myocardium: why not do it immediately?

Authors:  B L van Eck-Smit; E E van der Wall
Journal:  Br Heart J       Date:  1995-08

2.  The user-friendly nuclear cardiology report: what needs to be considered and what is included.

Authors:  M D Cerqueira
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

3.  The birth of a new radiopharmaceutical. Industrial perspective: from IND to NDA.

Authors:  L P Giering; J E Smith
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

4.  Quantitative comparison of single-isotope and dual-isotope stress-rest single-photon emission computed tomographic imaging for reversibility of defects.

Authors:  H M Siebelink; D Natale; A J Sinusas; F J Wackers
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

5.  Should early post-stress imaging be performed on a routine clinical basis for myocardial perfusion studies?

Authors:  Raymond Taillefer
Journal:  J Nucl Cardiol       Date:  2014-09-12       Impact factor: 5.952

6.  Myocardial perfusion imaging with 99mTc-labeled radiopharmaceuticals: How fast can a stress-rest same-day imaging protocol be completed?

Authors:  Raymond Taillefer
Journal:  J Nucl Cardiol       Date:  2016-04-04       Impact factor: 5.952

7.  Assessment of left ventricular ejection fraction with quantitative gated SPECT: accuracy and correlation with first-pass radionuclide angiography.

Authors:  E Vallejo; D P Dione; A J Sinusas; F J Wackers
Journal:  J Nucl Cardiol       Date:  2000 Sep-Oct       Impact factor: 5.952

8.  Defect reversibility using thallium-201 reinjection. Comparison of stress-redistribution-reinjection with stress-immediate reinjection.

Authors:  B L van Eck-Smit; A F Kuijper; A H Zwinderman; A V Bruschke; E K Pauwels; E E van der Wall
Journal:  Int J Card Imaging       Date:  1996-03

9.  Accuracy of detection of myocardial viability and residual infarct vessel stenoses with rest Tl-201 and adenosine Tc-99m sestamibi imaging after coronary reperfusion in dogs with experimental acute myocardial infarction.

Authors:  Kazuya Takehana; George A Beller; Mirta Ruiz; Frank D Petruzella; Denny D Watson; David K Glover
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.